Расширенный поиск

Современные подходы к профилактике пневмококковой инфекции

Полный текст:

Об авторах

Р. С. Козлов
НИИ антимикробной химиотерапии Государственного образовательного учреждения высшего профессионального образования "Смоленская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"

И. В. Андреева
НИИ антимикробной химиотерапии Государственного образовательного учреждения высшего профессионального образования "Смоленская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"

А. А. Мартинович
НИИ антимикробной химиотерапии Государственного образовательного учреждения высшего профессионального образования "Смоленская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"

Список литературы

1. Wright A.E., Morgan W.P., Cantab M.B. et al. Observation on prophylactic inoculations against pneumococcus infec tion, and on the results which have been achieved by it. Lancet 1914; 1: 87-95.

2. Heidelberg M., Avery O.T. The soluble specific substance of pneumococcus. J. Exp. Med. 1923; 38: 73-79.

3. Schiemann O., Casper W. Sind die spezifisch pracipitablen Substanzen der 3 Pneumokokkentypen Haptene? Z. Hyg. Infektionskr. 1927; 108: 220-257.

4. MacLeod C.M., Hodges R.G., Heidelberg M. et al. Preven tion of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 1945; 82: 445-465.

5. Austrian R., Gold J. Pneumococcal bacteremia with a special reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 1964; 60: 759-776.

6. Austrian R., Douglas R.M., Schiffman G. et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 1976; 89: 184-189.

7. Smit P., Oberholzer D., Hayden-Smith S. et al. Protective efficacy of pneumococcal polysaccharide vaccines. J.A.M.A. 1977; 238: 2613-2616.

8. Advisory Committee on Immunization Practices. Preven tion of pneumococcal diseases: recommendations of the advisory committee on immunization practices. Mortal. Morbid. Wkly Rep. 1997; 46: 1-24.

9. Butler J.C., Breiman R.F., Campbell J.F. et al. Polysaccha ride pneumococcal vaccine efficacy: an evaluation of cur rent recommendations. J.A.M.A. 1993; 270: 1826-1831.

10. Preventing pneumococcal bacteremia at patients at risk. Results of a matched case-control study. Arch. Intern. Med. 1995; 155: 2336-2340.

11. Sims R.V., Steinmann W.C., McConville J.H. et al. The clin ical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 1988; 108: 653-657.

12. Shapiro E.D., Berg A.T., Austrian R. et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 1991; 325: 1453-1460.

13. Jackson L.A., Neuzil K.M., Yu O. et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 2003; 348: 1747-1755.

14. Forrester H.L., Jahningen D.W., LaForce F.M. Inefficacy of pneumococcal vaccine in a high-risk population. Am. J. Med. 1987; 83: 425-430.

15. Johnstone J., Marrie T.J., Eurich D.T. et al. Effect of pneu mococcal vaccination in hospitalized adults with communi tyacquired pneumonia. Arch. Intern. Med. 2007; 167 (18): 1938-1943.

16. Sisk J.E., Moskowitz A.J., Whang W. et al. Cost!effectiveness of vaccination against pneumococcal bacteremia among elderly people. J.A.M.A. 1997; 278: 1333-1339.

17. Ogilvie I., Khoury A.E., Cui Y. et al Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a sys tematic review of conclusions and assumptions. Vaccine 2009; 27 (36): 4891-4904.

18. Fedson D.S., Musher D.M., Eskola J. Pneumococcal vaccine. In: Plotkin S.A., Orenstein W.A., Vaccines 3rd ed. Philadelphia: W.B. Saunders; 1999. 553-607.

19. Fine M.J., Smith M.A., Carson C.A. et al. Efficacy of pneumococcal vaccination in adults: a meta!analysis of random ized controlled trials. Arch. Intern. Med. 1994; 154: 2666-2677.

20. Jackson L.A., Benson P., Sneller V.1P. et al. Safety of revac cination with pneumococcal polysaccharide vaccine. J.A.M.A. 1999; 281: 243-248.

21. Sankilampi U., Honkanen P.O., Bloigu A. et al. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in patients in the elderly. J. Infect. Dis. 1997; 176: 1100-1104.

22. Brichacek B., Swindells S., Janoff E.N. et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 1996; 174: 1191-1199.

23. Katzenstein T.L., Gerstoft J., Nielsen H. Assessments of plas ma HIV RNA and CD4 cell counts after combined Pneumovax® and tetanus toxoid vaccination. Scand. J. Infect. Dis. 1996; 28: 239-241.

24. O'Dempsey T.J.D., McArdle T., Ceesay S.J. et al. Immunization with a pneumococcal capsular polysaccharide vac cine during pregnancy. Vaccine 1996; 14: 963-970.

25. Nuorti J.P., Butler J.C., Crutcher J.M. et al. An outbreak of pneumonia and bacteremia due to multidrug-resistant Streptococcus pneumoniae among unvaccinated nursing home residents. N. Engl. J. Med. 1998; 338: 1861-1868.

26. Centers for Disease Control and Prevention. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chronic!care facilities - Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May-June 1996. Mortal. Morbid. Wkly Rep. 1997; 46: 60-62.

27. Fiore A.E., Iverson C., Messmer T. et al. Outbreak of pneumonia in a long!term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J. Am. Geriatr. Soc. 1998; 46: 1112-1117.

28. Rodriguez-Barradas M.C., Tharapel R.A., Groover J.E. et al. Colonization by Streptococcus pneumoniae among human immunodeficiency virus!infected adults: prevalence of antibiotic resistance, impact of immunization, and charac terization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. J. Infect. Dis. 1997; 175: 590-597.

29. USPHS / IDSA Prevention of Opportunistic Infections Working Group. Prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997; 127: 922-946.

30. Rodriguez-Barradas M.C., Musher D.M., Kahart C., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vac!cine. J. Infect. Dis. 1992; 165: 553-556.

31. Target Product Profile and Technical Requirements. Pre tender Meeting Pneumococcal Vaccines under the AMC, UNICEF Supply Division, Copenhagen, 26 Aug. 2009. Copenhagen; 2009.

32. GAVI Alliance. Pneumococcal Vaccines: Suppliers, pipelines, and availability: 4th Annual network conference, 9-10 November 2006.

33. Black S., Shinefeld H., Fireman B. et al. Efficacy, safety and immunogenecity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Group. Pediatr. Infect. Dis. J. 2000; 19: 187-195.

34. Centers for Disease Control and Prevention (CDC). Inva sive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. Mortal. Morbid. Wkly Rep. 2008; 57 (6): 144-148.

35. Kyaw M.H., Lynfield R., Schaffner W. et al. Effect of introduction of the pneumococcal conjugate vaccine on drug resistant Streptococcus pneumoniae. N. Engl. J. Med. 2006; 354 (14): 1455-1463.

36. Grivea I.N., Panagiotou M., Tsantouli A.G. et al. Impact of heptavalent pneumococcal conjugate vaccine on nasopha ryngeal carriage of penicillin!resistant Streptococcus pneu moniae among day-care center attendees in central Greece. Pediatr. Infect. Dis. J. 2008; 27 (6): 519-525.

37. Eskola J., Kilpi T., Palmu A. et al. Efficacy of a pneumococ cal conjugate vaccine against acute otitis media. N. Engl. J. Med. 2001; 344 (6): 403-409.

38. Wysocki J., Galaj A., Omeсaca F. et al. Data presented at ISPPD 2008. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP, PneumoADIP Report, November 2008.

39. Hausdorff W.P. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 2007; 25 (13): 2406-2412.

40. Pneumococcal Regional Serotype Distribution for Pneumo coccal AMC TPP, PneumoADIP Report, November 2008. Available at:

41. Prymula R., Peeters P., Chrobok V. et al. Pneumococcal cap sular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367 (9512): 740-748.

42. Prevnar®. Pneumococcal 7!valent Conjugate Vaccine (Diphtheria CRM197 Protein). Product monograph. Manufactured by: Wyeth Pharmaceuticals. Available from: s%20PDFs/Prevnar_PM_Dec_22_2008_sub_Jan_8_2009. pdf

43. Synflorix®. Pneumococcal polysaccharide conjugate vaccine, 10-valent adsorbed. Approved Product Information. GlaxoSmithKline Australia Pty Ltd. Available from: dataproinfo/151/FileName/F95603879DCA33D25B69CF2D 7FE45D0D/PI_Synflorix.pdf

44. Rennels M.B., Edwards K.M., Keyserling H.L. et al. Safety and immunogenicity of heptavalent pneumococcal conjugated to CRM197 in United States infants. Pediatrics 1998; 101 (4, Pt 1): 604-611.

45. Center K.J., Strauss A. Safety experience with heptavalent pneumococcal CRM197!conjugate vaccine (Prevenar) since vaccine introduction. Vaccine 2009; 27 (25-26): 3281-3284.

46. Destefano F., Pfeifer D., Nohynek H. Safety profile of pneu mococcal conjugate vaccines: systematic review of pre and postlicensure data. Bull. Wld Hlth Org. 2008; 86 (5): 373-380.

47. Chevallier B., Vesikari T., Brzostek J. et al. Safety and reac togenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD!CV) when coadministered with routine childhood vaccines. Pediatr. Infect. Dis. J. 2009; 28 (4, Suppl.): S109- S118.

48. Sinha A., Levine O., Knoll M.D. et al. Cost!effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007; 369 (9559): 389-396.

49. Ongkasuwan J., Valdez T.A., Hulten K.G. et al. Pneumo coccal mastoiditis in children and the emergence of mul tidrugresistant serotype 19A isolates. Pediatrics 2008; 122 (1): 34-39.

50. Sampson J.S., Furlow Z., Whitney A.M. et al. Limited diver sity of Streptococcus pneumoniae psaA among pneumococ cal vaccine serotypes. Infect. and Immun. 1997; 65: 1967-1971.

51. Lock R.A., Paton J.C., Hansman D. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae infection. Microb. Pathogen. 1988; 5: 461-467.

52. Briles D.E., Hollingshead S.K., Swiatlo E. et al. PspA and PspC: Their potential for use as pneumococcal vaccines. Microb. Drug. Resist. 1997; 3: 401-408.

53. McDaniel L.S., Sheffield J.S., Delucchi P. et al. PspA, a sur face protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular serotype. Infect. Immun. 1991; 59: 222-228.

54. Wu H.-Y., Nahm M.H., Guo Y. et al. Intranasal immuniza tion of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 1997; 175: 839-846.

55. Nayak A.R., Tinge S.A., Tart R.C. et al. A live recombinant virulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect. and Immun. 1998; 66: 3744-3751.

56. McDaniel L.S., Loechel F., Benedict C. et al. Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae. Gene Ther. 1997; 4: 375-377.

Для цитирования:

Козлов Р.С., Андреева И.В., Мартинович А.А. Современные подходы к профилактике пневмококковой инфекции. Пульмонология. 2010;(4):88-95.

Просмотров: 3

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)